Armata Pharmaceuticals (ARMP) EBITDA (2013 - 2026)

Armata Pharmaceuticals has disclosed EBITDA across 14 years of filings, most recently posting -$8.8 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$8.8 million, down 7.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$37.2 million (up 7.85% YoY), and the FY2025 annual result was -$36.6 million, up 13.67% from the prior year.
• EBITDA came in at -$8.8 million for Q1 2026 at Armata Pharmaceuticals, up from -$13.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$6.8 million in Q2 2025 to a low of -$13.8 million in Q4 2025.
• The 5-year median for EBITDA is -$9.6 million (2023), against an average of -$9.7 million.
• Across the five-year window, EBITDA tumbled 70.77% in 2022 and soared 42.55% in 2025, its largest moves.
• Armata Pharmaceuticals' EBITDA stood at -$10.3 million in 2022, then rose by 7.25% to -$9.6 million in 2023, then retreated by 10.02% to -$10.5 million in 2024, then plunged by 31.16% to -$13.8 million in 2025, then jumped by 36.45% to -$8.8 million in 2026.
• The last three EBITDA figures came in at -$8.8 million (Q1 2026), -$13.8 million (Q4 2025), and -$7.8 million (Q3 2025), per Business Quant data.